2024 Revenues ($USD) : $4.98B

The Menarini Group, a privately held Italian pharmaceutical and diagnostics company headquartered in Florence, has a history spanning over 135 years. The company maintains a sizable global presence, with its products available in 140 countries and a workforce of over 17,000 employees. Menarini's operations are focused on therapeutic areas with high unmet needs, including cardiology, oncology, pneumology, gastroenterology, infectious diseases, diabetology, inflammation, and analgesia.

The company has a partnership with the AI biopharma pioneer Insilico Medicine. Elcin Barker Ergun, CEO of the Menarini Group, stated in January 2025 that the firm was "thrilled to enter our second collaboration with Insilico Medicine, a leader in the field of generative AI, for a highly selective and potentially best-in-class small molecule targeting a broad range of cancers. This asset will help us enter into new areas of high unmet need, expanding the tumor areas where we can help cancer patients with ground-breaking therapies.”

Menarini continues to invest in research and development across its nine R&D centers and operates 18 production sites globally, emphasizing innovation and international expansion.